GlassScriptPhysician profile
Juan P Suarez
NPI 1992794556
$9,658.07
in general payments reported to CMS, 2019-2025
48 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $2,013 · 2021: $1,820 · 2022: $1,435 · 2023: $1,281 · 2024: $956 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,673.61 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,223.09 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $879.94 | 2019-2025 | Ubrelvy, Linzess, Creon |
| Pfizer INC. | $729.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $654.00 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $615.31 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $555.28 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $375.41 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $228.91 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $189.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.21 | 2019-2022 | |
| Corcept Therapeutics | $161.47 | 2023-2025 | Korlym |
| Amarin Pharma, INC. | $153.85 | 2020-2023 | |
| Ibsa Pharma INC. | $137.21 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.97 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.